Group 1 - The core viewpoint of the article highlights the inclusion of the HPV vaccine in China's national immunization program, indicating a significant step in public health policy [1] - The announcement of the centralized procurement project for the bivalent human papillomavirus vaccine has a budget of approximately 425 million yuan, with a total quantity of 15.4465 million doses [1] - The maximum price per dose is set at no more than 27.5 yuan, which reflects the government's effort to make the vaccine more accessible [1]

Core Viewpoint - The inclusion of the HPV vaccine in the national immunization program indicates a significant government commitment to public health, with a centralized procurement project budgeted at approximately 425 million yuan for 15.4465 million doses, setting a price cap of no more than 27.5 yuan per dose [1] Group 1 - The Chinese government has announced a centralized procurement project for the bivalent human papillomavirus (HPV) vaccine as part of the national immunization program [1] - The total budget for this procurement project is approximately 425 million yuan [1] - The quantity of vaccines to be procured is 15.4465 million doses, with a price limit of 27.5 yuan per dose [1]